Munshi Renuka, Joshi Samidha, Panchal Falguni, Kumbhar Dipti, Chaudhari Pradip
Department of Clinical Pharmacology, TN Medical College & BYL Nair Hospital, Dr AR Nair Road, Mumbai Central, Mumbai, 400 008, India.
Department of Clinical Pharmacology, TN Medical College & BYL Nair Hospital, Dr AR Nair Road, Mumbai Central, Mumbai, 400 008, India.
J Ayurveda Integr Med. 2021 Jan-Mar;12(1):35-42. doi: 10.1016/j.jaim.2019.04.006. Epub 2019 Nov 7.
Osteoporosis is a public health problem in the elderly wherein a decrease in bone mass and mineral density increases the at risk of fractures. Panchatikta Ghrita (PG) is a classical Ayurvedic formulation that may help slow bone degeneration.
This experimental study was conducted to assess the efficacy of Panchatikta ghrita (PG) in protecting against postmenopausal osteoporosis in ovariectomized rats.
The experiment was initiated after Institutional Animal Ethics Committee approval. 96 female Sprague Dawley rats were divided into 8 groups viz. sham control (NC), diseased control (DC), vehicle control (VC), 3 test drug (PG) groups (PG1, PG2 & PG3 - 0.9, 1.8 and 2.7gm/kg body weight respectively) and 2 standard control (SC) groups - SC1 received 17α-ethinylestradiol 1μg/kg/day while SC2 received alendronate (7mg/kg/week). Study medications were administereddaily for four months. Bone specific biomarkers viz. osteocalcin and TRAP-5b were estimated at baseline and end of study. Animals were sacrificed on day 121 and their femurs and tibiae were harvested for histomorphometric analysisand bone microarchitectural studies.
Serum osteocalcin and TRAP-5b showed significant increase (p < 0.001) in levels in DC group as compared to sham controls. All 3 doses of PG decreased bone specific biomarker levels with maximal effect seen with highest dose of PG similar to that seen with standard drugs. PG also significantly improved bone micro architectural parameters like bone mineral density and mineral content at higher dose levels. Decrease in osteoclasts and significant dose dependent increase in bone hardness and elasticity was seen with PG which was comparable to standard drugs.
PG increased bone mineral density and content, decreased turnover of bone specific biomarkers and osteoclast formation, indicating its protective effect against experimentally induced postmenopausal osteoporosis.
骨质疏松症是老年人中的一个公共卫生问题,其中骨量和矿物质密度的降低会增加骨折风险。潘查蒂卡酥油(PG)是一种经典的阿育吠陀配方,可能有助于减缓骨质退化。
本实验研究旨在评估潘查蒂卡酥油(PG)对去卵巢大鼠绝经后骨质疏松症的预防效果。
实验经机构动物伦理委员会批准后开始。将96只雌性Sprague Dawley大鼠分为8组,即假手术对照组(NC)、疾病对照组(DC)、赋形剂对照组(VC)、3个受试药物(PG)组(PG1、PG2和PG3,分别为0.9、1.8和2.7克/千克体重)以及2个标准对照组(SC)——SC组1接受17α-炔雌醇1微克/千克/天,而SC组2接受阿仑膦酸钠(7毫克/千克/周)。研究药物每日给药四个月。在基线和研究结束时估计骨特异性生物标志物,即骨钙素和抗酒石酸酸性磷酸酶5b(TRAP-5b)。在第121天处死动物,采集其股骨和胫骨进行组织形态计量分析和骨微结构研究。
与假手术对照组相比,DC组血清骨钙素和TRAP-5b水平显著升高(p < 0.001)。所有3个PG剂量均降低了骨特异性生物标志物水平,最高剂量的PG效果最佳,与标准药物相似。PG在较高剂量水平时还显著改善了骨微结构参数,如骨矿物质密度和矿物质含量。PG可使破骨细胞数量减少,骨硬度和弹性显著剂量依赖性增加,与标准药物相当。
PG增加了骨矿物质密度和含量,降低了骨特异性生物标志物的周转率和破骨细胞形成,表明其对实验性诱导的绝经后骨质疏松症具有保护作用。